CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
* Participants received at least one treatment with a cellular therapy product in an eligible index trial.
* Participant was withdrawn, early discontinued or completed an eligible index trial.
* Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Exclusion Criteria:

-This study has no exclusion criteria.

主要终点：Number of Participants With any Adverse Events of Special Interest (AESI) · Up to 180 months
次要终点：Number of Participants With Cellular Product-related Serious Adverse Events (SAEs)；Overall Survival (OS)；Percentage of Participants With Persistent Product

• Cellular Therapy · Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.